126 related articles for article (PubMed ID: 38810473)
1. Comprehensive quantitative radiogenomic evaluation reveals novel radiomic subtypes with distinct immune pattern in glioma.
Sun Y; Zhang Y; Gan J; Zhou H; Guo S; Wang X; Zhang C; Zheng W; Zhao X; Li X; Wang L; Ning S
Comput Biol Med; 2024 Jul; 177():108636. PubMed ID: 38810473
[TBL] [Abstract][Full Text] [Related]
2. Imaging phenotypes from MRI for the prediction of glioma immune subtypes from RNA sequencing: A multicenter study.
Duan J; Zhang Z; Chen Y; Zhao Y; Sun Q; Wang W; Zheng H; Liang D; Cheng J; Yan J; Li ZC
Mol Oncol; 2023 Apr; 17(4):629-646. PubMed ID: 36688633
[TBL] [Abstract][Full Text] [Related]
3. Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value.
Lin P; Peng YT; Gao RZ; Wei Y; Li XJ; Huang SN; Fang YY; Wei ZX; Huang ZG; Yang H; Chen G
J Cancer Res Clin Oncol; 2020 May; 146(5):1253-1262. PubMed ID: 32065261
[TBL] [Abstract][Full Text] [Related]
4. Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction.
Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Jain R; Lee SK
Eur Radiol; 2020 Jul; 30(7):3834-3842. PubMed ID: 32162004
[TBL] [Abstract][Full Text] [Related]
5. Radiomic profiling for insular diffuse glioma stratification with distinct biologic pathway activities.
Duan W; Wang Z; Ma Z; Zheng H; Li Y; Pei D; Wang M; Qiu Y; Duan M; Yan D; Ji Y; Cheng J; Liu X; Zhang Z; Yan J
Cancer Sci; 2024 Apr; 115(4):1261-1272. PubMed ID: 38279197
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging-based radiomic features for extrapolating infiltration levels of immune cells in lower-grade gliomas.
Zhang X; Liu S; Zhao X; Shi X; Li J; Guo J; Niedermann G; Luo R; Zhang X
Strahlenther Onkol; 2020 Oct; 196(10):913-921. PubMed ID: 32025804
[TBL] [Abstract][Full Text] [Related]
7. Impact of signal intensity normalization of MRI on the generalizability of radiomic-based prediction of molecular glioma subtypes.
Foltyn-Dumitru M; Schell M; Rastogi A; Sahm F; Kessler T; Wick W; Bendszus M; Brugnara G; Vollmuth P
Eur Radiol; 2024 Apr; 34(4):2782-2790. PubMed ID: 37672053
[TBL] [Abstract][Full Text] [Related]
8. Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature.
Li Y; Liu X; Qian Z; Sun Z; Xu K; Wang K; Fan X; Zhang Z; Li S; Wang Y; Jiang T
Eur Radiol; 2018 Jul; 28(7):2960-2968. PubMed ID: 29404769
[TBL] [Abstract][Full Text] [Related]
9. Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas.
Pei D; Guan F; Hong X; Liu Z; Wang W; Qiu Y; Duan W; Wang M; Sun C; Wang W; Wang X; Guo Y; Wang Z; Liu Z; Xing A; Guo Z; Luo L; Liu X; Cheng J; Zhang B; Zhang Z; Yan J
Eur Radiol; 2023 May; 33(5):3455-3466. PubMed ID: 36853347
[TBL] [Abstract][Full Text] [Related]
10. MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting.
Sakai Y; Yang C; Kihira S; Tsankova N; Khan F; Hormigo A; Lai A; Cloughesy T; Nael K
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33121211
[TBL] [Abstract][Full Text] [Related]
11. Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas.
Jiang C; Kong Z; Zhang Y; Liu S; Liu Z; Chen W; Liu P; Liu D; Wang Y; Lyu Y; Zhao D; Wang Y; You H; Feng F; Ma W
Neuroradiology; 2020 Jul; 62(7):803-813. PubMed ID: 32239241
[TBL] [Abstract][Full Text] [Related]
12. Radiogenomics of lower-grade gliomas: a radiomic signature as a biological surrogate for survival prediction.
Qian Z; Li Y; Sun Z; Fan X; Xu K; Wang K; Li S; Zhang Z; Jiang T; Liu X; Wang Y
Aging (Albany NY); 2018 Oct; 10(10):2884-2899. PubMed ID: 30362964
[TBL] [Abstract][Full Text] [Related]
13. Radiogenomics correlation between MR imaging features and mRNA-based subtypes in lower-grade glioma.
Liu Z; Zhang J
BMC Neurol; 2020 Jun; 20(1):259. PubMed ID: 32600353
[TBL] [Abstract][Full Text] [Related]
14. Deriving quantitative information from multiparametric MRI via Radiomics: Evaluation of the robustness and predictive value of radiomic features in the discrimination of low-grade versus high-grade gliomas with machine learning.
Ubaldi L; Saponaro S; Giuliano A; Talamonti C; Retico A
Phys Med; 2023 Mar; 107():102538. PubMed ID: 36796177
[TBL] [Abstract][Full Text] [Related]
15. Radiogenomics to characterize the immune-related prognostic signature associated with biological functions in glioblastoma.
Liu D; Chen J; Ge H; Yan Z; Luo B; Hu X; Yang K; Liu Y; Liu H; Zhang W
Eur Radiol; 2023 Jan; 33(1):209-220. PubMed ID: 35881182
[TBL] [Abstract][Full Text] [Related]
16. Radiogenomic analysis of vascular endothelial growth factor in patients with diffuse gliomas.
Sun Z; Li Y; Wang Y; Fan X; Xu K; Wang K; Li S; Zhang Z; Jiang T; Liu X
Cancer Imaging; 2019 Oct; 19(1):68. PubMed ID: 31639060
[TBL] [Abstract][Full Text] [Related]
17. MRI features predict p53 status in lower-grade gliomas via a machine-learning approach.
Li Y; Qian Z; Xu K; Wang K; Fan X; Li S; Jiang T; Liu X; Wang Y
Neuroimage Clin; 2018; 17():306-311. PubMed ID: 29527478
[TBL] [Abstract][Full Text] [Related]
18. Machine Learning-Based Multiparametric Magnetic Resonance Imaging Radiomics for Prediction of H3K27M Mutation in Midline Gliomas.
Kandemirli SG; Kocak B; Naganawa S; Ozturk K; Yip SSF; Chopra S; Rivetti L; Aldine AS; Jones K; Cayci Z; Moritani T; Sato TS
World Neurosurg; 2021 Jul; 151():e78-e85. PubMed ID: 33819703
[TBL] [Abstract][Full Text] [Related]
19. The Value of Enhanced MR Radiomics in Estimating the IDH1 Genotype in High-Grade Gliomas.
Niu L; Feng WH; Duan CF; Liu YC; Liu JH; Liu XJ
Biomed Res Int; 2020; 2020():4630218. PubMed ID: 33163535
[TBL] [Abstract][Full Text] [Related]
20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
